Eugene May
Eugene F. May, M.D.

Eugene F. May, M.D.

Eugene F. May, M.D.

Neurology, Neuro-Ophthalmology

Clinical Interests / Special Procedures Performed

Botulinum Treatment, Dizziness, Double Vision, Eye Movement Disorders, Multiple Sclerosis, Multiple Sclerosis Clinics at SNI, Myasthenia Gravis, Neuro-Ophthalmology, Neurotology, Optic Nerve Disorders, Vertigo

  • Accepting Children: Yes
  • Accepting New Patients: Yes
  • Accepting Medicare: Yes
  • Accepting Medicaid/DSHS: Yes
Payment Methods Accepted:

Medicare, Medicaid/DSHS, Bill Insurance, VISA, Master Card, Cash, Check, Payment Plan, Money Order

Insurance Accepted:

Contact this office for accepted insurance plans.

Additional Information:

Fellow, American Academy of Neurology
Board of Trustees, National Multiple Sclerosis Society, Greater Northwest Chapter

Philosophy of Care

My practice is limited to neuro-ophthalmology, the field of medicine that bridges neurology and ophthalmology. I see patients whose visual symptoms are or may be due to neurologic problems. I also have a special interest in diagnosis and treatment of vestibular disorders. Patients with vestibular disorders have vertigo, dizziness, and imbalance.

Personal Interests

I enjoy spending time with my wife and children and our toy fox terrier.

Medical School

University of Chicago


Walter Reed Army Medical Center


Walter Reed Army Medical Center

Board Certifications

American Board of Psychiatry and Neurology

Professional Associations:

North American Neuro-ophthalmology Society, American Academy of Neurology

Additional Information:

Fellow, American Academy of Neurology
Board of Trustees, National Multiple Sclerosis Society, Greater Northwest Chapter

Multiple sclerosis, optic neuritis, ischemic optic neuropathy, pseudotumor cerebri, optical coherence tomography

Advances in Vision Assessment in Multiple Sclerosis

Over the past several years, the visual function of people living with multiple sclerosis (MS) has been increasingly recognized as an important marker of quality of life in MS, and as a useful indicator of the severity and activity of MS both clinically, and in MS research. Measurement of a person’s ability to see faded letters (low contrast acuity) has been found to be an excellent marker of MS visual function, and its change over time is related to MS disease activity. Optical coherence tomography (OCT), which measures the health of optic nerves and retinas in individuals with MS, is providing an explosion of data that has increased our insight into the extent, course, and pathology of multiple sclerosis.
At this year’s North American Neuro-ophthalmology Society meeting, data was presented on another technique that is being developed and refined for use in the MS population, a questionnaire about visual quality of life.  The ..

Vision Problems with MS: Can AP-4 (Ampyra) help?

Each optic nerve contains approximately one million nerve cells (neurons) that connect the eye to the brain. Inflammation from multiple sclerosis (MS) can affect the optic nerves. Therefore, it is very common for people with MS to have vision problems.

When MS inflammation affects optic nerve neurons, they may lose their protective myelin coating, a process called demyelination. This caused signals through the neurons to slow down, resulting in blurred vision.

Medications may repair myelin, but studies are limited.

4-aminopyridine (4-AP) is a medicine used to treat symptoms of MS caused by demyelination. It stabilizes movement of potassium ions through the surface of demyelinated neurons, making it easier for them to conduct signals.

Historically, 4-AP has only been available through compounding pharmacies, so studies of its use have been ...

Pharmacologic Treatment of Nystagmus in Multiple Sclerosis

At least half of all people with multiple sclerosis (MS) are expected to have nystagmus at some point during the course of their illness. Nystagmus results from demyelination that involves the brainstem or cerebellar eye movement pathways. While it may be asymptomatic, it often causes blurred vision or oscillopsia. The extent of the visual disturbance is directly related to the velocity of the slow phase of the nystagmus.

In MS patients with chronic nystagmus, the most common form is an acquired pendular nystagmus (APN), which is almost always accompanied by optic atrophy, and often by internuclear ophthalmoplegia (INO).

Numerous treatment trials have demonstrated the efficacy of pharmacologic treatment of chronic symptomatic nystagmus. Treatment should be considered in individuals in whom blurred vision or oscillopsia is severe enough to warrant the potential risk of medication side effects. As a general rule, drugs used to treat nystagmus are titrated slowly upwards from a low dose to either efficacy or tolerance.

The two most effective medications for APN in MS are....

Results 1-3 of 3
  • 1


Neuro-ophthalmic Consultants Northwest
1229 Madison
Suite 615
Seattle, WA 98104
Phone: (206) 386-2700
Fax: (206) 386-2703
9:00 AM to 5:00 PM
9:00 AM to 5:00 PM
9:00 AM to 12:00 PM

9:00 AM to 5:00 PM
10:30 AM to 5:00 PM

Map & Directions

Physicians: Is this your profile? Click here for info